CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

被引:18
|
作者
Guegan, Jean-Philippe [1 ]
Pollet, Justine [2 ]
Ginestier, Christophe [3 ]
Charafe-Jauffret, Emmanuelle [3 ]
Peter, Marcus E. [4 ]
Legembre, Patrick [5 ]
机构
[1] Explicyte, Cours Argonne, F-33000 Bordeaux, France
[2] Univ Limoges, Technol Core Facil BISCEm, CHU Limoges, US042,Inserm,UMS CNRS 2015, Limoges, France
[3] Aix Marseille Univ, CNRS, INSERM, Inst Paoli Calmettes,CRCM Mol Oncol Equipe Labell, Marseille, France
[4] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[5] Univ Limoges, UMR CNRS 7276, CRIBL, INSERM 1262, Limoges, France
关键词
SIGNALING PATHWAY; NITRIC-OXIDE; SOMATIC MUTATIONS; FAS LIGAND; PROTEIN; EXPRESSION; GENE; RECEPTOR; CELLS; APOPTOSIS;
D O I
10.1016/j.isci.2021.103538
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CD95 expression is preserved in triple-negative breast cancers (TNBCs), and CD95 loss in these cells triggers the induction of a pro-inflammatory program, promoting the recruitment of cytotoxic NK cells impairing tumor growth. Herein, we identify a novel interaction partner of CD95, Kip1 ubiquitination-promoting complex protein 2 (KPC2), using an unbiased proteomic approach. Independextly of CD95L, CD95/KPC2 interaction contributes to the partial degradation of p105 (NF-kappa B1) and the subsequent generation of p50 homodimers, which transcriptionally represses NF-kappa B-driven gene expression. Mechanistically, KPC2 interacts with the C-terminal region of CD95 and serves as an adaptor to recruit ReIA (p65) and KPC1, which acts as E3 ligase promoting the degradation of p105 into p50. Loss of CD95 in TNBC cells releases KPC2, limiting the formation of the NF-kappa B inhibitory homodimer complex (p50/p50), promoting NF-kappa B activation and the production of pro-inflammetory cytokines, which might contribute to remodeling the immune landscape in TNBC cells.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] A Novel Tetravalent CD95/Fas Fusion Protein With Superior CD95L/FasL Antagonism
    Lang, Isabell
    Paulus, Oliver
    Zaitseva, Olena
    Wajant, Harald
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2025, 93 (02) : 441 - 451
  • [2] The CD95(APO-1/Fas)/CD95L system
    Krammer, PH
    TOXICOLOGY LETTERS, 1998, 103 : 131 - 137
  • [3] Analysis of apoptotic markers Fas/FasL (CD95/CD95L) expression on the lymphocytes in patients with acute coronary syndrome
    Bossowska, Anna
    Bossowski, Artur
    Galar, Bogdan
    KARDIOLOGIA POLSKA, 2007, 65 (08) : 883 - 892
  • [4] Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-κB activation
    Woo, SH
    Park, IC
    Park, MJ
    An, S
    Lee, HC
    Jin, HO
    Park, SA
    Cho, HY
    Lee, SJ
    Gwak, HS
    Hong, YJ
    Hong, SI
    Rhee, CH
    INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (04) : 596 - 606
  • [5] Immunohistochemical characterization of Fas (CD95) and Fas Ligand (FasL/CD95L) expression in the injured brain: Relationship with neuronal cell death and inflammatory mediators
    Grosjean, M. B.
    Lenzlinger, P. M.
    Stahel, P. F.
    Yatsiv, I.
    Shohami, E.
    Trentz, O.
    Kossmann, T.
    Morganti-Kossmann, M. C.
    HISTOLOGY AND HISTOPATHOLOGY, 2007, 22 (03) : 235 - 250
  • [6] Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism
    Nabipour, Iraj
    Kalantarhormozi, Mohammadreza
    Assadi, Majid
    Jafari, Seyed Mojtaba
    Gharibi, Mohammad
    Ahmadi, Esmaeil
    Sanjdideh, Zahra
    ENDOCRINE, 2010, 38 (03): : 406 - 411
  • [7] Modification of tumor cells with fas (CD95) antigen gene and fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer
    Motomu Shimizu
    Takayuki Yoshimoto
    Akio Matsuzawa
    Yasutaka Takeda
    Molecular Biotechnology, 2003, 25 : 79 - 87
  • [8] Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer
    Shimizu, M
    Yoshimoto, T
    Matsuzawa, A
    Takeda, Y
    MOLECULAR BIOTECHNOLOGY, 2003, 25 (01) : 79 - 87
  • [9] Apigenin Increases Natural Killer Cytotoxicity to Human Hepatocellular Carcinoma Expressing HIF-1α through High Interaction of CD95/CD95L
    Lee, Hwan Hee
    Cho, Hyosun
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2022, 32 (04) : 397 - 404
  • [10] Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma
    Blaes, Jonas
    Thome, Carina M.
    Pfenning, Philipp-Niclas
    Ruebmann, Petra
    Sahm, Felix
    Wick, Antje
    Bunse, Theresa
    Schmenger, Torsten
    Sykora, Jaromir
    von Deimling, Andreas
    Wiestler, Benedikt
    Merz, Christian
    Jugold, Manfred
    Haberkorn, Uwe
    Abdollahi, Amir
    Debus, Juergen
    Gieffers, Christian
    Kunz, Claudia
    Bendszus, Martin
    Kluge, Michael
    Platten, Michael
    Fricke, Harald
    Wick, Wolfgang
    Lemke, Dieter
    MOLECULAR CANCER RESEARCH, 2018, 16 (05) : 767 - 776